Rosehip (Rosa canina) for osteoarthritis: the GOPO trials

← Back to articles

Rosehip powder standardized for the galactolipid GOPO has shown modest, fairly consistent pain relief in hip and knee osteoarthritis across several randomized trials. The effect size is small — not large enough to impress anyone expecting dramatic results, but consistent enough that pooled analyses treat it as a legitimate adjunct. Most of the data come from a single proprietary preparation and several trials funded by its manufacturer, which is the main reason to keep expectations grounded.

The active constituent: GOPO

Most of the clinical evidence concerns a standardized Rosa canina powder marketed in Europe as Hyben Vital / LitoZin, which contains a galactolipid abbreviated GOPO (a galactosyl-glycerol esterified with the omega-3 fatty acid alpha-linolenic acid). A 2019 systematic review of the pharmacology (Gruenwald and colleagues) catalogued the plausible anti-inflammatory mechanisms: rosehip constituents inhibit chemotaxis of peripheral-blood neutrophils, reduce C-reactive protein levels, dampen NF-κB signaling, and inhibit pro-inflammatory enzymes including COX-1, COX-2 and 5-LOX. In other words the proposed mechanism is broad anti-inflammatory and antioxidant activity from a mixture of compounds — phenolics, terpenoids, galactolipids, carotenoids and vitamin C — rather than a single cyclooxygenase-blocking drug.

The pivotal individual trials

Two Danish-led crossover trials anchor the early evidence, both using 5 g/day of the standardized powder. Rein and colleagues (2004) randomized 112 osteoarthritis patients to rosehip or placebo for three months each; responders (by reduction in joint pain) reached 66% on active treatment versus 36% on placebo, with general well-being also improving — though the trial showed a strong "carryover" effect that complicates the crossover. Winther and colleagues (2005) randomized 94 hip- or knee-OA patients in a similar design and found a significant reduction in WOMAC pain after just three weeks, a significant drop in rescue-medication use, and improvements in stiffness, disability and global severity by three months. A 2007 systematic review (Rossnagel and colleagues) judged both trials methodologically strong (Jadad 5) but small, and concluded the powder had a "moderate" effect.

The meta-analysis

The most rigorous synthesis is the patient-data meta-analysis by Christensen and colleagues (2008), which pooled three placebo-controlled studies (287 patients, median trial duration three months, all supported by the manufacturer). It found a standardized mean difference for pain of 0.37 (95% CI 0.13–0.60) favoring rosehip — a small-to-moderate effect — with no detectable heterogeneity across trials. Patients on rosehip were about twice as likely to respond as those on placebo, corresponding to a number-needed-to-treat of six. The authors were careful to note the data were sparse and that the efficacy and safety "need evaluation and independent replication in a future large-scale/long-term trial" — a caveat that, more than a decade later, still largely stands.

How it compares with other joint supplements

The standardized-mean-difference of about 0.37 puts rosehip in the same broad efficacy bucket as glucosamine and chondroitin — statistically detectable, clinically modest. It is not a substitute for an NSAID when an NSAID is genuinely needed, but for someone who wants a low-risk adjunct and tolerates a daily powder, the evidence is at least as good as for the more familiar joint nutraceuticals, and the mechanism is distinct.

Safety and practical considerations

Adverse events in the trials were infrequent and mild — primarily gastrointestinal (mild nausea, loose stools). No major safety signals emerged over the three-to-six-month study periods. The vitamin C content of rosehip is real but the absolute dose at clinical intakes is modest, so the theoretical iron-absorption interaction is unlikely to be material at 5 g/day. Pregnancy and lactation data are sparse, so it is best avoided there by default.

Bottom line

Standardized rosehip powder (GOPO) at 5 g/day is a reasonable, well-tolerated evidence-based adjunct for hip or knee osteoarthritis pain, with a small effect size, onset in the three-to-four-week range, and a favorable safety profile. The honest caveat is that the supporting trials are small and were funded by the manufacturer of the branded powder, and an independent large-scale replication is still lacking. It is an add-on, not a replacement for weight management, physical therapy, or pharmacologic treatment in moderate-to-severe disease.